Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

General Motors

Let's take a look at two stocks that Ark Invest keeps buying, seemingly for reasons unknown.

Is Ark Invest Wrong About These 2 Stocks?

ARK Innovation ETF

Coinbase

Roku

Pandemic superstar fund, ARKK Innovation ETF, has been facing tremendous pressure as its stock continues to dip. Economic conditions and the losses recorded by its holdings have contributed to its woes. We believe buying the dip on ARKK is not wise at this time.

Cathie Woods Is In A Mess Right Now

Telemedicine has a sizable growth runway ahead.

Could This Healthcare Stock Be Berkshire Hathaway's Next Pick?

Viatris

They present very different kinds of bargains.

2 Stocks That Are Ridiculously Cheap Right Now

An analyst bucks the trend and lifts her price target on the stock.

Why Teladoc Health Flew 9% Higher on Friday

Teladoc has dropped more than 60% since the beginning of April, destroying billions of shareholder wealth. Business growth remained intact, but compressing margins and the need to spend massively on marketing are noteworthy issues.

Is Teladoc Stock A Buy Or Sell After April's Crash?

Peloton

Shopify

Once prosperous investments throughout the pandemic, the high-flying days for these stocks is well over in 2022.

Pandemic Winners Turned Losers: Should You Still Buy?

While there's no hiding from a tough first quarter, user metrics remained solid.

Teladoc's Stock Is on Life Support -- Can It Be Revived?

Amazon

Amazon Should Buy Teladoc Right Now -- Seriously

In this article, I explain my bullish thesis for Teladoc and Telemedicine. Teladoc's Q1'22 earnings weren't particularly impressive, but it's still too early to call it quits.

Teladoc: My Bullish Thesis

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Teladoc To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 9, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC).If you suffered losses exceeding $50,000 investing in Teladoc stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/TDOC.

Teladoc Update

New York, New York--(Newsfile Corp. - May 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (NYSE: TDOC) ("Teladoc" or the "Company"). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.

Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why

Corsair Gaming

Netflix

PayPal

Warner Bros Discovery Inc

These stocks fell enough after investors gave up, creating a tremendous buying chance for patient investors. The post 7 Sold-Off Stocks Ready to Surge From Here appeared first on InvestorPlace.

7 Sold-Off Stocks Ready to Surge From Here

First-quarter revenue miss reset Teladoc's prospects for shareholders, pressuring the company to accelerate its multi-product launch. The post Investors Should Take a Bigger Position When Teledoc Posts a Strong Quarter appeared first on InvestorPlace.

Investors Should Take a Bigger Position When Teledoc Posts a Strong Quarter

Teladoc Health collapsed following weak guidance for 2022. Cathie Wood loaded up on the dip buying 600K shares on April 28.

Teladoc Health: Following Cathie Wood For Once

Teladoc has been caught up in the wave as the tech sector has sunk. But it's getting increasingly hard to dismiss TDOC stock's specific flaws, as well.

Teladoc Health's Vital Signs Are Not Getting Better

Los Angeles, California--(Newsfile Corp. - May 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or "the Company") (NYSE: TDOC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teladoc announced its first quarter 2022 financial results on April 27,...

Investigation Notice: The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $100,000 to Contact the Firm

The Real Reason Teladoc Is Struggling

The negative outlook for TDOC is exaggerated, and the market sees the glass as half empty even though the revised full-year 2022 revenue guidance is not bad. Additional impairment downside is possible but limited. Moreover, there's no substantial material change in the business apart from the lower advertising yields, elongated selling cycles, increased discount rate, and lower multiples.

Teladoc: Revisiting My Thesis

Bilibili

Zoom Video

A lot of stocks have been hit hard, even as their fundamentals are moving in the right direction.

3 Stocks Still Growing Despite Being Down More Than 80%

Los Angeles, California--(Newsfile Corp. - May 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or "the Company") (NYSE: TDOC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teladoc announced its first quarter 2022 financial results on April 27,...

Investigation Alert: The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $100,000 to Contact the Firm

Teladoc's Q1 results were weak, but management's 2022 guidance cut and the goodwill impairment expense of $6.6B were simply horrific developments at the company. While the Livongo acquisition has turned into a disaster, Teladoc's BetterHelp (mental health) business is also facing headwinds due to heightened competition and wage inflation.

Teladoc: Cracks Widen, But Thesis Is Not Broken

The stock's sell-off was an extreme reaction to its earnings report. A rally this year could follow.

Why Teladoc's Q1 Results Really Weren't That Bad

Did the stock market overreact to Teladoc's first-quarter earnings report?

News for Teladoc Stock (TDOC)